Drugs /

gallium ga 68-edotreotide

Back to Drugs List

Overview

NCI Definition [1]:
A radioconjugate consisting of the octreotide derivative edotreotide labeled with gallium 68 (Ga-68) with potential application in somatostatin receptor (SSTR) imaging in conjunction with positron emission tomography (PET). Similar to octreotide, gallium Ga 68-edotreotide binds to SSTRs, especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells and their metastases, thereby allowing for imaging of SSTR-expressing cells upon PET. Gallium Ga 68-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelating the substituted octreotide to Ga-68 via the macrocyclic chelating agent dodecanetetraacetic acid (DOTA).

Clinical Trials

View Clinical Trials for gallium ga 68-edotreotide

Gallium ga 68-edotreotide has been investigated in 3 clinical trials, of which 1 is open and 2 are closed. Of the trials investigating gallium ga 68-edotreotide, 1 is early phase 1 (0 open) and 2 are phase 2 (1 open).

SSTR2 Expression, SSTR1 Expression, and SSTR3 Expression are the most frequent biomarker inclusion criteria for gallium ga 68-edotreotide clinical trials.

Malignant solid tumor and neuroendocrine tumor are the most common diseases being investigated in gallium ga 68-edotreotide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Gallium Ga 68-Edotreotide
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Gallium Ga 68-Edotreotide
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating gallium ga 68-edotreotide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
gallium ga 68-edotreotide, gallium ga 68-dotatoc, ga-68-dota-tyr(3)-octreotide, ga-68-dota-toc, ga-68 dotatoc, ga-68 dota0-tyr3-octreotide, edotreotide gallium ga-68, 68ga-dota-toc, 68ga-dota-d-phe1-tyr3-octreotide
NCIT ID [1]:
C101369

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.